MicroBioGen and Novonesis develop breakthrough non-GM yeast to increase production, reliability and efficiency for the ethanol industry globally.
MicroBioGen, an Australian biotechnology company known for its cutting-edge yeast innovation, has unveiled a groundbreaking new product, Innova® Delta, developed in collaboration with global biotech leader Novonesis (formerly Novozymes).
Innova® Delta is the latest advancement in ethanol production, offering non-genetically modified (non-GM) yeast strains that deliver operational performance on par with genetically modified yeasts. This innovation addresses the stringent regulations in Europe and Australia that limit the use of genetically modified organisms. With Innova® Delta, ethanol plants can achieve an average two percent greater ethanol yield, reduce fermentation times by up to 25 percent, and enhance resilience with a temperature tolerance of up to 36 degrees Celsius. The yeast also excels in fermentations exceeding 50 hours, improving efficiency and minimising bottlenecks.
This ninth product in the Innova® suite exemplifies MicroBioGen and Novonesis’ longstanding partnership, with decades of research and thousands of development hours invested in its creation. MicroBioGen CEO Geoff Bell highlighted the significance of this innovation in advancing sustainable aviation fuel (SAF) and the global ethanol industry, expressing excitement about Australia’s potential in SAF development.
Jens Kolind, Vice President of Planetary Health at Novonesis, noted that Innova® Delta is a game-changer for ethanol producers restricted to non-GM yeast, providing increased yield, reduced fermentation times, and greater operational control. This breakthrough builds on the success of the Innova® yeast range, which has leveraged MicroBioGen’s innovative technology to enhance ethanol production since 2018.
With its robust performance and sustainable approach, Innova® Delta is set to revolutionise ethanol production globally.